![Study design schematic for the open-label extension study. AE, adverse... | Download Scientific Diagram Study design schematic for the open-label extension study. AE, adverse... | Download Scientific Diagram](https://www.researchgate.net/profile/Herbert-Baraf/publication/233396586/figure/fig4/AS:289187577253918@1445959099647/Figure1-Study-design-schematic-for-the-open-label-extension-study-AE-adverse-event-IR.png)
Study design schematic for the open-label extension study. AE, adverse... | Download Scientific Diagram
![Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program - ScienceDirect Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0021915018313455-gr1.jpg)
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program - ScienceDirect
![Figure 8, Study Design of Phase II Open-Label Extension (LSBL99) - Clinical Review Report: Belimumab (Benlysta) - NCBI Bookshelf Figure 8, Study Design of Phase II Open-Label Extension (LSBL99) - Clinical Review Report: Belimumab (Benlysta) - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK565231/bin/cl4f8.jpg)
Figure 8, Study Design of Phase II Open-Label Extension (LSBL99) - Clinical Review Report: Belimumab (Benlysta) - NCBI Bookshelf
![Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram](https://www.researchgate.net/publication/337470199/figure/fig2/AS:836912487088133@1576546894872/Flow-chart-showing-the-study-design-of-the-open-label-extension-phase-OLE-of-the_Q640.jpg)
Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram
![Disposition for all patients entering the open-label extension (OLE)... | Download Scientific Diagram Disposition for all patients entering the open-label extension (OLE)... | Download Scientific Diagram](https://www.researchgate.net/profile/Herbert-Baraf/publication/233396586/figure/fig3/AS:289023215063066@1445919912895/Figure2-Disposition-for-all-patients-entering-the-open-label-extension-OLE-study-ITT.png)
Disposition for all patients entering the open-label extension (OLE)... | Download Scientific Diagram
![Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial - The Lancet Rheumatology Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial - The Lancet Rheumatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/10cfb42a-cd7b-4a5d-bc3a-0cb46a2046e3/gr2.jpg)
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial - The Lancet Rheumatology
![An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-019-1857-3/MediaObjects/13075_2019_1857_Fig1_HTML.png)
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text
![Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study - The Lancet Respiratory Medicine Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study - The Lancet Respiratory Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/09b4693d-be29-4706-bb5a-934e3a7910fd/gr1.jpg)
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study - The Lancet Respiratory Medicine
![Understanding Clinical Trial Terminology: What is a Long-Term Extension or Open-Label Extension Study? - Concert Pharmaceuticals Understanding Clinical Trial Terminology: What is a Long-Term Extension or Open-Label Extension Study? - Concert Pharmaceuticals](https://www.concertpharma.com/wp-content/uploads/2020/08/shutterstock_1165019548-scaled-e1597922554371.jpg)